We have demonstrated previously that endothelin-1 (ET-1) may stimulate interleukin-6 (IL-6) release from 3T3-L1 adipocytes. In this study, we further examined the combined effect of ET-1 and cyclic adenosine monophosphate (cAMP) on IL-6 release. METHODS: IL-6 release was measured by enzyme-linked immuosorbent assay. Reverse transcriptase-PCR and real-time PCR analyses were used to determine cellular mRNA levels. A luciferase reporter driven by promoter (À1310/ þ 198) of mouse IL-6 gene was transfected into 3T3-L1 adipocytes to monitor IL-6 transcription. RESULTS: ET-1 and cAMP induced IL-6 release in a synergistic manner that can be attributed to their synergistic induction of IL-6 gene expression, as evidenced by IL-6 mRNA analysis and the IL-6 promoter reporter assay. Both ET A and ET B receptors seem to be involved. In addition, enhanced IL-6 promoter activity can be similarly induced by ET-1 and catecholamines (epinephrine and norepinephrine). The cooperative interaction between ET-1 and cAMP on IL-6 expression seems distinctive, as no other proinflammatory cytokines, such as tumor necrosis factor-a (TNF-a) and IL-1b, are similarly affected. In fact, cAMP inhibited ET-1-stimulated TNF-a and IL-1b expressions in adipocytes. Furthermore, injection of mice with epinephrine and ET-1 induced a tremendously synergistic increase in serum IL-6 levels. Nevertheless, whereas cAMP induced IL-6 expression in RAW264.7 mouse macrophages, ET-1 had no effect on either the basal or the cAMP-induced IL-6 expression. CONCLUSION: ET-1 and epinephrine may boost plasma IL-6 levels in mice in a synergistic manner, probably through their synergistic induction of IL-6 expression in adipocytes. SIGNIFICANCE: This study should provide a new perspective for treating IL-6-related diseases, especially those accompanied with elevated ET-1 and catecholamine levels.
INTRODUCTION
Besides functioning as an energy depot, adipocyte is now recognized as an endocrine organ 1, 2 and is strongly suggested to have an important and initiating role in insulin resistance. 3 In addition to releasing free fatty acids, adipocyte secretes a wide range of proinflammatory cytokines that may be related to insulin resistance. 2 Among these proinflammatory adipokines released by adipocytes, tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) appear to be the most important for inducing insulin resistance, due to their direct inhibitory effects on insulin signaling as well as their indirect anti-insulin effects. 4 Nevertheless, the observations that the plasma IL-6 levels are higher in obese men, 5 the subcutaneous adipose tissue releases IL-6, but not TNF-a in vivo, and 15 --35% of circulating IL-6 is contributed by adipose tissue, 6 make IL-6 a potential connecting factor between obesity and insulin resistance.
Endothelin-1 (ET-1) is a 21-amino-acid polypeptide mainly secreted by endothelial cells. Besides being a potent vasoconstrictor, 7 ET-1 may be closely related to insulin resistance: it was shown to inhibit insulin-stimulated glucose uptake in muscles 8, 9 and adipocytes. 10 --12 As IL-6 is well known to induce insulin resistance, we tested and found that ET-1 may stimulate the expression and secretion of IL-6 in 3T3-L1 adipocytes. 13 Interestingly, we also found that ET-1 induced IL-6 expression seems to use the same signaling pathways as it uses to induce Glut1 expression. 13, 14 In addition to inducing IL-6 expression in fat cells, 15, 16 b-adrenergic agonists (via cyclic adenosine monophosphate (cAMP)) may synergistically act with ET-1 to enhance Glut1 expression in 3T3-L1 adipocytes. 17, 18 In the present study, we further test the hypothesis that ET-1 and cAMP may also have a synergistic induction of IL-6 expression and release in adipocytes. It is indeed the case. Moreover, we demonstrate for the first time that ET-1 and epinephrine have a synergistic effect on elevating circulating IL-6 levels in mice, probably via their synergistic effect on IL-6 expression in adipocytes.
MATERIALS AND METHODS Materials
Dexamethasone, IBMX (3-isobutyl-1-methylxanthine), epinephrine, actinomycin D, 8-bromo cAMP and bovine serum albumin were obtained from Sigma (St. Louis, MO, USA). ET-1 was purchased from Peninsula Laboratories (San Carlos, CA, USA). Mouse IL-6 promoter reporter (pLuc-IL6) was constructed as previously described. 13 Cell culture 3T3-L1 cells were grown and differentiated into adipocytes in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, glutamine, penicillin and streptomycin as described earlier. 17 Briefly, 2 days after confluence (day 0), the medium was removed and fresh medium containing 0.5 mM IBMX and 0.25 mM dexamethasone was added. After another 3 days, the medium was replaced with fresh culture medium and the cultures were then maintained as described above. By day 8, more than 90% of the cells differentiated into rounded cells with lipid droplets. On days 8 --12, differentiated 3T3-L1 adipocytes were used for experiments throughout this study. RAW264.7 macrophages were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and glutamine, penicillin and streptomycin and maintained at 37 1C and 5% CO 2 .
Measurement of IL-6 secretion After various treatments, the medium was collected and stored at À80 1C for future use. IL-6 protein contents in samples from the same set of experiments were assayed by the same enzyme-linked immuosorbent assay kit (ELISA Quantikine Mouse IL-6 Immunoassay, R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instruction. The coefficient of variation for intra-assay and inter-assay were 7% and 9%, respectively.
RNA preparation, reverse transcriptase-PCR and real-time PCR Total cellular RNA was prepared using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instruction. Complementary DNA synthesis was performed at 65 1C using 2 --5 mg of total RNA of 3T3-L1 adipocytes or RAW264.7 macrophages as the template primed with random hexamers. Aliquots of the complementary DNAs were subjected to PCR amplification using Platinum Taq DNA polymerase under optimal conditions in the presence of appropriate pairs of primers. IL-6 :
The PCR products were then analyzed by 2% agarose gel electrophoresis. For real-time PCR, complementary DNA was quantified using TaqMan Gene Expression Assays (IL-6: Product no. Mm00446190_m1; TNF-a: Product no. Mm00443260_g1; IL-1b: Product no. Mm00434228_m1) (Applied Biosystems, Foster City, CA, USA).
Transfection and luciferase assay
Transfection of 3T3-L1 adipocytes or RAW264.7. macrophages was performed by electroporation as described earlier. 13 pCMVb (Promega, Madison, WI, USA) or pRL Renilla luciferase (Promega) was included in each transfection to correct for the transfection efficiency. After electroporation, cells were immediately mixed with serum-supplemented medium and seeded onto six-well culture plates. After another 24 h, cells were incubated in the presence of serum-free medium for 2 h before being treated with tested reagents for another 16 --24 h. The cells were then lyzed with a lysis buffer (25 mM Tris-phosphate, 2 mM 1,2-diaminocyclohexane-N,N,N,N,-tetraacetic acid, 2 mM dithiothreitol, 10% glycerol and 1% Triton X-100, pH 7.8). Cell lysates obtained following centrifugation at 12 000 g for 5 min at 4 1C were used for the measurement of b-galactosidase (b-galactosidase Enzyme Assay System, Promega) and luciferase activities (LucLite kit, Packard Instrument Co. or Dual-Luciferase Assay System, Promega).
Administration of ET-1 and epinephrine into mice
Sixty male C57BL mice (17 --26 g body weight) obtained from the Animal Center of National Yang-Ming University were housed in six per cage in a temperature-(20 --22 1C) and light-controlled (alternating 12-h light/12-h dark cycle, light on 0700 hours) room. They were fed on regular diet chow and water ad libitum. After 1 week of acclimatization, mice were used for experiments with laboratory procedures under the guidelines of the Taiwan Government Guide for the Care and Use of Laboratory Animals. After overnight fasting, mice for treatments were assigned randomly into three groups (18 mice per group). Six mice without any treatment served as time zero controls. Mice in groups I, II and III received intraperitoneal injection of 1 mg ET-1, 2 mg epinephrine or 1 mg ET-1 plus 2 mg epinephrine in 100 ml saline per 100 g body weight, respectively, and were sacrificed by cervical dislocation at 1, 2 and 3 h after injections. Blood samples were taken by heart puncture. Serum was separated by centrifugation and stored at À20 1C until being assayed for IL-6 contents by enzyme-linked immuosorbent assay kits. Statistical differences were determined by Student's t-test.
RESULTS
Synergistic effect of ET-1 and cAMP on IL-6 secretion To determine the combined effect of ET-1 and cAMP on IL-6 secretion, 3T3-L1 adipocytes were treated with 8-bromo cAMP and varying concentrations of ET-1 or vice versa for 8 h and measured for the released IL-6 in the medium. As shown in Figures 1a and b , a synergism between ET-1 and 8-bromo cAMP on IL-6 release was observed. Although ET-1 at 10 nM (the optimal concentration) had only a relatively small enhancing effect on IL-6 release (from 0.02 to 0.12±0.02 ng per 10 6 cells, Po0.01), in the concomitant presence of 0.5 mM 8-bromo cAMP, which alone increased IL-6 release to 0.48 ± 0.03 ng per 10 6 cells (Po0.001), the IL-6 release was elevated to 1.07±0.05 ng per 10 6 cells (Po0.001), much higher than the sum of the IL-6 release induced by ET-1 and 8-bromo cAMP alone ( Figure 1a ). Similarly, a synergism between 10 nM ET-1 and varying concentrations of 8-bromo cAMP on IL-6 release was observed ( Figure 1b ). As the maximal synergistic effect (the effect of combined ET-1 and campÀ(sum of the effect of ET-1 and cAMP alone)) was observed at 10 nM ET-1 and 0.5 mM 8-bromo cAMP, these concentrations were used throughout this study. In addition, time-dependent effects of ET-1, 8-bromo cAMP and a combination of both also demonstrated the synergism between ET-1 and cAMP on IL-6 secretion ( Figure 1c ).
Synergistic effect of ET-1 and cAMP on IL-6 gene expression As proinflammatory cytokines are released as they are produced, the secretory process of IL-6 is unlikely to be subjected to regulation and the enhancing effect of ET-1 and 8-bromo cAMP on IL-6 secretion is probably due to augmented gene expression. To test this possibility, a transcription inhibitor actinomycin D was used. As shown in Figure 2a , in the presence of actinomycin D, the enhancing effect of ET-1 was completely eliminated, whereas the effect of 8-bromo cAMP or ET-1 plus 8-bromo cAMP was inhibited by approximately 95% and 97%, respectively, suggesting that the primary target site of regulation by ET-1 and cAMP is the transcription of IL-6 gene. This notion is substantiated by the finding that IL-6 mRNA levels, as determined by Reverse transcriptase-PCR or real-time PCR, were augmented by ET-1 and 8-bromo cAMP in a synergistic manner (Figure 2b) .
To further determine if IL-6 transcription is similarly enhanced by ET-1 and cAMP, cells were transfected with IL-6 promoter reporter (pLuc-IL6) and treated with ET1, 8-bromo cAMP and a combination of both. The results showed that ET-1 and 8-bromo cAMP alone both enhanced IL-6 promoter activity and in the presence of both ET-1 and 8-bromo cAMP, the promoter activity was further enhanced in a synergistic manner (Figure 2c ). Given that ET-1-stimulated IL-6 transcription is NF-kB-dependent 13 and ET-1 activation of NF-kB is inhibited by cAMP, 18 it is conceivable that in the simultaneous presence of 8-bromo cAMP, the direct contribution of ET-1 on IL-6 transcription is suppressed. Thus, the additional increase in the promoter activity in response to ET-1 plus cAMP over cAMP alone should represent the true synergistic effect, further suggesting that ET-1 and cAMP signaling pathways cooperate in a way to greatly facilitate cAMP-induced IL-6 gene expression. Moreover, the synergistic effect of ET-1 and cAMP on IL-6 promoter activity can be mimicked by ET-1 and epinephrine/ norepinephrine, catecholamoines known to activate b-adrenergic receptor and increase cAMP levels in adipocytes 19 ( Figure 2c ).
Involvement of both ET A and ET B receptors in the synergistic effect of ET-1 and cAMP on IL-6 promoter activity ET-1 has been shown to stimulate lipolysis via the ET A receptor but inhibit the antilipolytic effect of insulin via the ET B receptor in adipocytes. 20, 21 Although we showed previously that ET-1 stimulated IL-6 secretion from 3T3-L1 adipocytes via the ET A receptor, 13 the synergistic effect of ET-1 and cAMP on IL-6 secretion is not necessary to be mediated by the same receptor.
As the synergistic effect of ET-1 and cAMP is mainly attributable to their effects on IL-6 gene expression, we employed the promoter assay to assess which type ET receptor was involved by using BQ610 and BQ788, selective antagonists for ET A and ET B receptor, respectively. 20 As shown in Figure 3 , neither BQ610 nor BQ788 had any significant influence on cAMP-stimulated IL-6 promoter activity. In accord with our earlier report, 13 ET-1-stimulated promoter activity was inhibited by BQ610 (k80%, Po0.01). BQ788 had only a minor and non-significant effect. Regarding the promoter activity in response to a combination of ET-1 and cAMP, nevertheless, both BQ610 and BQ788 significantly reduced the response and in the presence of both antagonists, the promoter activity was decreased nearly to that in response to cAMP alone. By using the difference between the increase in promoter activity in response to ET-1 plus cAMP ([ET
Combined effect of ET-1 and cAMP on TNF-a and IL-1b expressions Besides IL-6, proinflammatory cytokines, such as TNF-a and IL-1b, are produced by both immune cells and adipocytes, and are associated with insulin resistance and related disease. 22 We therefore examined if ET-1 and cAMP might have synergistic effect on the expressions of these two cytokines in 3T3-L1 adipocytes. As shown in Figure 4 , treatment of 3T3-L1 adipocytes with ET-1 significantly enhanced both TNF-a and IL-1b mRNA levels to approximately 2.4-and 2.0-fold of control, respectively. Whereas 8-bromo cAMP alone had no significant influence, it abolished the increase in TNF-a and IL-1b mRNA levels in response to ET-1. As it is well known that activation of NF-kB leads to increased transcription of both TNF-a and IL-1b genes, 22 the inhibition of ET-1-induced TNF-a and IL-1b expressions by cAMP probably reflects its inhibition of ET-1-induced activation of NF-kB. 18 Thus, it appears that only IL-6 expression in adipocytes can be induced by ET-1 and cAMP in a synergistic manner.
Synergistic effect of ET-1 and epinephrine on elevating circulating IL-6 levels in mice The finding that ET-1 and epinephrine had a synergistic effect on IL-6 gene expression prompted us to test if these two agents have similar synergistic effect on circulating IL-6 in mice. We thus injected mice with ET-1, epinephrine and a combination of both and determined the serum levels of IL-6 afterwards. As shown in Figure 5 , at 2 h after injections, ET-1 and epinephrine alone increased serum IL-6 levels gradually from a basal level of 0.02 ± 0.01 ng ml À1 to 0.76 ± 0.04 ng ml À1 (38-fold of basal, Po0.001) and 0.88 ± 0.31 ng ml À1 (44-fold of basal, Po0.05), respectively. At 3 h after injections, serum IL-6 levels declined to 0.29±0.03 ng ml À1 (15-fold of basal, Po0.01) and 0.33±0.01 ng ml À1 (17-fold of control, Po0.001) for ET-1 and epinephrine, respectively, but still significantly above the basal levels. On the other hand, injection of both ET-1 and epinephrine elevated serum IL-6 levels faster and greater. At 1 h after injection, serum IL-6 levels were increased to approximately 6 ng ml À1 (300-fold of control, Po0.001), much higher than the additive effect of ET-1 and epinephrine alone (Po0.01). Thereafter, IL-6 levels declined quickly to reach approximately 0.4 ng ml À1 (20-fold of control, Po0.001) at 3 h. These data thus clearly show that ET-1 and epinephrine have a synergistic effect on elevation of circulating IL-6 levels in mice. Although this phenomenon may reflect the synergistic effect of ET-1 and epinephrine on IL-6 secretion from adipocytes, the possibility that IL-6 may be released from other sources cannot be excluded.
ET-1 has no effect on IL-6 gene expression in macrophages Macrophage is the major source of IL-6 and activation of the b2-adrenergic receptor on macrophages has been reported to induce IL-6 production via a cAMP-dependent mechanism. 23 To examine whether ET-1 and cAMP may have a synergistic effect on IL-6 expression in macrophages, we determined the effect of ET-1, 8-bromo cAMP and a combination of both on IL-6 expression in RAW 264.7 mouse macrophages. As shown in Figure 6 , cAMP significantly stimulated IL-6 expression as determined by Reverse transcriptase-PCR, real-time PCR (Po0.01) or promoter activity analysis (Po0.05). On the contrary, ET-1 had no effect on IL-6 expression or on facilitating the increase induced by cAMP. Therefore, the tremendous increase in circulating IL-6 levels in response to ET-1 and epinephrine in mice probably reflects their synergistic effect on IL-6 secretion from adipocytes.
DISCUSSION
In the present study, we clearly demonstrate that (1) ET-1 and cAMP can induce a synergistic increase in IL-6 secretion from adipocytes ( Figure 1) , (2) ET-1 and cAMP/catecholamines can Induction of IL-6 expression by ET-1 and cAMP S-P Chai et al stimulate a synergistic induction of IL-6 expression in adipocytes ( Figure 2 ) and (3) ET-1 and epinephrine can induce a tremendously synergistic increase in circulating IL-6 levels in mice ( Figure 5 ). As epinephrine is well known for acting on adipocytes through b-adrenergic receptor/Gs/adenylate cyclase/cAMP cascade 19 and ET-1 has no effect on basal or cAMP-induced IL-6 expression in macrophages (Figure 6 ), a major source of IL-6 production in addition to adipocytes, 24 this study strongly implies that the tremendous boosting effect of ET-1 and epinephrine on circulating IL-6 levels in mice is mediated by their synergistic induction of IL-6 expression in adipocytes rather than macrophages. Nevertheless, we cannot exclude the possible contribution from other IL-6 secreting cells 25 that might also release IL-6 in response to ET-1 and epinephrine in a synergistic manner.
The finding that the mouse plasma IL-6 response to ET-1 and epinephrine was quick (within 1 h) and robust (B300-fold of basal) underscores the importance of the interaction between endothelial cell and catecholamines in producing IL-6. Indeed, in many cases such as severe trauma, septic shock and major surgery, where the plasma IL-6 levels are extremely high, 26 it may also be accompanied with elevated ET-1 and catecholamine levels. 27 --29 Thus, in addition to immune cells, IL-6 release from adipocytes as provoked by elevated ET-1 and catecholamines probably makes a major and significant contribution.
Besides adipocytes, adipose tissue contains blood vessels, infiltrated macrophages and other cells, 30 and is innervated by sympathetic nerves. 31 Consequently, higher norepinephrine release from sympathetic nerve endings in response to physical or psychological stress 32 could act on neighboring adipocytes via b-adrenergic receptors. 16 In some cases, psychological stress may elevate plasma IL-6, 33,34 ET-1 (ref. 35) as well as catecholamine levels; 36 then it is conceivable that in addition to catecholamine's stimulatory effect on IL-6 release from macrophages, 23 the cooperative interaction between catecholamines (via cAMP) and ET-1 on inducing IL-6 production from adipocytes should also make a great contribution in stress-induced IL-6 levels. Furthermore, as elevated IL-6 is closely associated with insulin resistance, type 2 diabetes mellitus and cardiovascular disease, 24 chronic exposure to stress may bring vulnerability to these IL-6-related diseases.
Given that ET-1 and cAMP may boost Glut1 gene expression in a synergistic manner in 3T3-L1 adipocytes 17 and ET-1 seems to stimulate Glut1and IL-6 gene expressions through a similar signaling pathway, 13, 14 it is of interest to compare the potential transcription factors that may be involved in Glut1 and IL-6 transcriptions. Our earlier study demonstrated that the synergistic effect of ET-1 and cAMP on Glut1 transcription was mediated by a ternary complex Sp1/AP-1/pCREB bound to the enhancer 2 region. 18 Although NF-kB is required for the effect of ET-1 alone, it is not involved in the synergistic effect of ET-1 and cAMP on Glut1 transcription. Importantly, the segment (À1310/ þ 198) we used for IL-6 promoter activity assay also contains binding sites for NF-kB, Sp1, AP-1 and pCREB as predicted by the Transcription Element Search System program (http://www.cbil.upenn.edu/ cgi-bin/tess/tess) and UCSC Genome Bioinformatics (http:// genome.ucsc.edu), implying that Sp1/AP-1/pCREB complex might also be involved in the stimulation of IL-6 transcription. NF-kB is unlikely to be involved owing to its inactivation by cAMP. 18 On the other hand, as cAMP can activate both CREB and AP-1, 18 these two transcription factors are potential mediators for the action of cAMP. Furthermore, besides these response elements, the IL-6 promoter contains putative binding sites for C/EBPa and C/EBPb, either or both of them might also have a role in enhancing IL-6 gene expression in response to ET-1 and cAMP.
In summary, we have demonstrated that ET-1 via both ET A and ET B receptors may act synergistically with cAMP/catecholamine to stimulate IL-6 expression in adipocytes. This phenomenon in adipocytes seems unique, as the expressions of other proinflammatory cytokines as TNF-a and IL-1b are not similarly affected. In addition, we show that ET-1 and epinephrine may boost plasma IL-6 levels in mice in a synergistic manner. As ET-1 has no effect on IL-6 expression in macrophages, the promoting effect of ET-1 and epinephrine probably reflects their synergistic induction of IL-6 production in adipocytes. Thus, our results suggest that adipocytes have a significant role in elevating IL-6 levels under conditions when ET-1 and catecholamine levels are both high. It further implies that the IL-6 response to ET-1 and catecholamines in obesity should be even higher due to the greater adipose tissue mass. As elevated plasma IL-6 levels are associated with many diseases, the finding in this study should provide a new perspective for treating IL-6-related diseases, especially those accompanied with elevated ET-1 and catecholamine levels. For example, blocking both ET A and ET B receptors with non-selective antagonists should be an efficient treatment to lower IL-6 levels as well as to bring beneficial outcome.
